Cetuximab-related infusion reaction rate in cancer patients differs by race.

  title={Cetuximab-related infusion reaction rate in cancer patients differs by race.},
  author={Elias Kiwan and Eric R. Siegel and Laura Hutchins and A M Maddox and Rangaswamy Govindarajan and Ahmed Mazin Safar and Issam Makhoul},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={29 15_suppl},
e14075 Background: Cetuximab, an anti-EGFR IgG1 chimeric monoclonal antibody, is approved in colorectal (CRC) and head and neck (H&N) cancers and is being used in other solid tumors. Severe infusion reactions (IR) are noted in <3% of pts who received the drug in the U.S. The incidence of IR in Arkansas has been consistently higher than the rest of the country and tended to cluster in certain groups. METHODS Details on all cancer patients treated with ANY dose of cetuximab between 1/2004 and… CONTINUE READING